Asthma treatment

http://www.healasthma.com past six monthsthe past twelve months Search Hint Use the source navigation bar below to quickly narrow or broaden your search by geographic area. – . Chicago Tribune – RESEARCH SUGGESTS GENES GUIDE RESPONSE TO DRUG Researchers said this week that they had found a way to predict how people will respond to an asthma drug by looking at their genes.Tiny differences called single nucleotide polymorphisms, SNPs, cannot dictate response on their own, but they combine in predictable ways to affect a patient’s ability to use the drug, the team at Genaissance Pharmaceuticals, Inc. and the University of Cincinnati found.These combinations of genetic variation are called genetic haplotypes, and… . Dura lauded for solid sales in st quarter Dura Pharmaceuticals is getting solid sales from its respiratory products, but it has problems with its developmental Spiros inhaler, analysts say. Richard R. Vietor of Merrill Lynch points out that Dura’s first-quarter sales were impressive, even though coughs, colds and flu weren’t rampant in the period.But the company’s pending repurchase of Spiros Development, the off-balance sheet research and development vehicle for Spiros, is a question… . / / B bizdigthu Economy grew at fastest pace in years The supercharged U.S. economy soared to an annual growth rate of . percent in the final three months of the strongest performance in years, the government said today.The increase in the gross domestic product � the country�s total output of goods and services � marked a better-than-expected upward revision from an estimate a month ago.The higher final estimate reflected new data showing that… . Los Angeles Times – Anti-Asthma Drug Is Found to Reduce Need for Hospitalization The anti-asthma drug ipratropium can significantly reduce the need for hospitalization in children who experience a severe asthma attack, according to a study published in today’s New England Journal of Medicine.But the medication, sold under the brand name Atrovert, made little difference for patients with moderate asthma, the study said.More than asthmatic children who came to the Children’s Hospital of the King’s Daughters in Norfolk, Va.,… . The Buffalo News – COPLEY PHARMACEUTICAL IS FINED . MILLION A pharmaceutical company accused of cutting corners in the manufacture of four generic drugs agreed Wednesday to plead guilty to federal fraud charges and pay a . million fine.For six years, Copley Pharmaceutical Inc. conspired to defraud the Food and Drug Administration by changing FDA-approved manufacturing methods and then failing to inform regulators, the plea agreement said Prosecutors said the penalty is the largest criminal fine on record against a drug company and reflects… . (Madison, WI) – UW STUDY EXAMINES `INHALERS FOR MILD ASTHMA, USE IT ONLY WHEN YOU NEED IT, REPORT SAYS If you use an “inhaler” to treat mild asthma, UW-Madison has some research results for you If you use the inhaler only when you feel you need it, your asthma will be controlled just as effectively as it would should you use the inhaler on a regular basis.That discovery, which will be published in today’s edition of the New England Journal of Medicine, ends a long debate about how to treat millions of people who have mild cases of asthma.Some… . The Dallas Morning News – Copley Pharmaceutical changes executives after recalls, inquiry BOSTON – Copley Pharmaceutical Co., rocked by a federal probe into the recall of two drugs, has named a new chairman and hired an outsider as chief executive in an effort to focus on overseas markets.The maker of generic drugs said Monday it has appointed Gabriel R. Cipau, a Hungarian-born chemist and executive from Burroughs Wellcome Co., to be president and CEO. Kenneth N. Larsen, who served as interim president, was named the company’s chairman.Copley also appointed… Copley Pharmaceutical Co. names new chairman, CEO The company is shifting its focus toward overseas markets as it deals with a drug recall investigation by federal authorities. BOSTON – Copley Pharmaceutical Co., rocked by a federal investigation into the recall of two drugs, has named a new chairman and hired an outsider as chief executive in an effort to focus on overseas markets.The maker of generic drugs said yesterday that it has appointed Gabriel R. Cipau, a Hungarian-born chemist and executive from Burroughs Wellcome Co., to be president and CEO. Kenneth N. Larsen, who served as interim president, was named chairman.Copley also appointed founder… . Los Angeles Times – Sepracor’s Most Promising Drugs Sepracor Inc. is researching the removal of molecules that cause side effects in some of medicine’s best-known drugs. Some of the company’s most promising prospects, including the drug’s brand name, generic name, purpose, side effects being removed and stage of development Seldane Terfenadine; non-sedating allergy pill; heart arrhythmia; patent issued, in final tests on people; launch target .Orudis Ketoprofen; painkiller; gastric distress;… . Business BUSINESS BRIEFCASE DOW RISES The stock market climbed yesterday, given a boost by a good employment report and steadier interest rates. The Dow Jones industrial average ended . points higher at , . and concluded the week down . points. COPLEY SUIT An Alabama class-action lawsuit against Canton-based Copley Pharmaceutical Inc. claims the company allowed a rare but potentially deadly bacteria into its asthma inhalers. The suit, filed in Coffee County Circuit Court, claims Copley was negligent… –